{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:07:15Z","timestamp":1783969635775,"version":"3.55.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-026-00921-3","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:32:25Z","timestamp":1783924345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR-Cas9-based therapies for Huntington\u2019s disease and Friedreich\u2019s ataxia: mechanisms, advances, and future perspectives"],"prefix":"10.1007","volume":"27","author":[{"given":"Abha Ravikumar","family":"Mundada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amogh Reddy","family":"Badikol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0291-6314","authenticated-orcid":false,"given":"Karthik","family":"Mangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"921_CR1","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/J.CSBJ.2020.08.031","volume":"18","author":"Y Xu","year":"2020","unstructured":"Xu Y, Li Z (2020) CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Comput Struct Biotechnol J 18:2401. https:\/\/doi.org\/10.1016\/J.CSBJ.2020.08.031","journal-title":"Comput Struct Biotechnol J"},{"key":"921_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.MICROB.2025.100344","volume":"7","author":"K Saeed","year":"2025","unstructured":"Saeed K, Ayub F, Durrani MA, Mujahid M (2025) CRISPR Cas systems: from bacterial defense mechanisms to revolutionary tools reshaping genetic research and translation therapeutics. Microbe 7:100344. https:\/\/doi.org\/10.1016\/J.MICROB.2025.100344","journal-title":"Microbe"},{"key":"921_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/SCIENCE.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I et al (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816\u2013821. https:\/\/doi.org\/10.1126\/SCIENCE.1225829","journal-title":"Science"},{"key":"921_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/J.TRECAN.2018.03.002","volume":"4","author":"RD Chow","year":"2018","unstructured":"Chow RD, Chen S (2018) Cancer CRISPR screens in vivo. Trends Cancer 4:349. https:\/\/doi.org\/10.1016\/J.TRECAN.2018.03.002","journal-title":"Trends Cancer"},{"key":"921_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTN.2025.102636","volume":"36","author":"N Kalter","year":"2025","unstructured":"Kalter N, Fuster-Garc\u00eda C, Silva A et al (2025) Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges. Mol Ther Nucleic Acids 36:102636. https:\/\/doi.org\/10.1016\/J.OMTN.2025.102636","journal-title":"Mol Ther Nucleic Acids"},{"key":"921_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/CSHPERSPECT.A024240","volume":"7","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC (2017) Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med 7:a024240. https:\/\/doi.org\/10.1101\/CSHPERSPECT.A024240","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"921_CR7","doi-asserted-by":"publisher","first-page":"NS20180060","DOI":"10.1042\/NS20180060","volume":"2","author":"E Clark","year":"2018","unstructured":"Clark E, Johnson J, Dong YN et al (2018) Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease. Neuronal Signal 2:NS20180060. https:\/\/doi.org\/10.1042\/NS20180060","journal-title":"Neuronal Signal"},{"key":"921_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/EMMM.201000064","volume":"2","author":"T Punga","year":"2010","unstructured":"Punga T, B\u00fchler M (2010) Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol Med 2:120. https:\/\/doi.org\/10.1002\/EMMM.201000064","journal-title":"EMBO Mol Med"},{"key":"921_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/PBI.12736","volume":"15","author":"J Murovec","year":"2017","unstructured":"Murovec J, Pirc \u017d, Yang B (2017) New variants of CRISPR RNA-guided genome editing enzymes. Plant Biotechnol J 15:917. https:\/\/doi.org\/10.1111\/PBI.12736","journal-title":"Plant Biotechnol J"},{"key":"921_CR10","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1021\/ACS.BIOCHEM.1C00354","volume":"60","author":"K Babu","year":"2021","unstructured":"Babu K, Kathiresan V, Kumari P et al (2021) Coordinated Actions of Cas9 HNH and RuvC Nuclease Domains Are Regulated by the Bridge Helix and the Target DNA Sequence. Biochemistry 60:3783\u20133800. https:\/\/doi.org\/10.1021\/ACS.BIOCHEM.1C00354","journal-title":"Biochemistry"},{"key":"921_CR11","doi-asserted-by":"publisher","first-page":"E2010","DOI":"10.1073\/PNAS.1716855115","volume":"115","author":"BR Lemos","year":"2018","unstructured":"Lemos BR, Kaplan AC, Bae JE et al (2018) CRISPR\/Cas9 cleavages in budding yeast reveal templated insertions and strand-specific insertion\/deletion profiles. Proc Natl Acad Sci U S A 115:E2010\u2013E2047. https:\/\/doi.org\/10.1073\/PNAS.1716855115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"921_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22126397","author":"B Song","year":"2021","unstructured":"Song B, Yang S, Hwang GH et al (2021) Analysis of NHEJ-based DNA repair after CRISPR-mediated DNA cleavage. Int J Mol Sci. https:\/\/doi.org\/10.3390\/IJMS22126397","journal-title":"Int J Mol Sci"},{"key":"921_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/IJMS21186461","volume":"21","author":"H Yang","year":"2020","unstructured":"Yang H, Ren S, Yu S et al (2020) Methods Favoring Homology-Directed Repair Choice in Response to CRISPR\/Cas9 Induced-Double Strand Breaks. Int J Mol Sci 21:1\u201320. https:\/\/doi.org\/10.3390\/IJMS21186461","journal-title":"Int J Mol Sci"},{"key":"921_CR14","doi-asserted-by":"publisher","first-page":"103553","DOI":"10.1016\/J.DNAREP.2023.103553","volume":"130","author":"JJ Loparo","year":"2023","unstructured":"Loparo JJ (2023) Holding it together: DNA end synapsis during non-homologous end joining. DNA Repair (Amst) 130:103553. https:\/\/doi.org\/10.1016\/J.DNAREP.2023.103553","journal-title":"DNA Repair (Amst)"},{"key":"921_CR15","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/J.OMTN.2024.102344","volume":"35","author":"H Liao","year":"2024","unstructured":"Liao H, Wu J, VanDusen NJ et al (2024) CRISPR-Cas9-mediated homology-directed repair for precise gene editing. Mol Ther Nucleic Acids 35:102344. https:\/\/doi.org\/10.1016\/J.OMTN.2024.102344","journal-title":"Mol Ther Nucleic Acids"},{"key":"921_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/J.OMTN.2023.04.012","volume":"32","author":"KM Fichter","year":"2023","unstructured":"Fichter KM, Setayesh T, Malik P (2023) Strategies for precise gene edits in mammalian cells. Mol Ther Nucleic Acids 32:536. https:\/\/doi.org\/10.1016\/J.OMTN.2023.04.012","journal-title":"Mol Ther Nucleic Acids"},{"key":"921_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/S10565-019-09489-1","volume":"35","author":"F Yan","year":"2019","unstructured":"Yan F, Wang W, Zhang J (2019) CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9. Cell Biology Toxicol 2019 35:6. https:\/\/doi.org\/10.1007\/S10565-019-09489-1","journal-title":"Cell Biology Toxicol 2019"},{"key":"921_CR18","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1038\/s41467-021-24454-5","volume":"12","author":"MJ Schmidt","year":"2021","unstructured":"Schmidt MJ, Gupta A, Bednarski C et al (2021) Improved CRISPR genome editing using small highly active and specific engineered RNA-guided nucleases. Nat Commun 12:4219. https:\/\/doi.org\/10.1038\/s41467-021-24454-5","journal-title":"Nat Commun"},{"key":"921_CR19","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1042\/BCJ20170793","volume":"475","author":"A Eid","year":"2018","unstructured":"Eid A, Alshareef S, Mahfouz MM (2018) CRISPR base editors: genome editing without double-stranded breaks. Biochem J 475:1955. https:\/\/doi.org\/10.1042\/BCJ20170793","journal-title":"Biochem J"},{"key":"921_CR20","doi-asserted-by":"publisher","first-page":"592623","DOI":"10.3389\/FGENE.2020.592623\/BIBTEX","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Bi D, Qin G et al (2020) Cytosine Base Editor (hA3A-BE3-NG)-Mediated Multiple Gene Editing for Pyramid Breeding in Pigs. Front Genet 11:592623. https:\/\/doi.org\/10.3389\/FGENE.2020.592623\/BIBTEX","journal-title":"Front Genet"},{"key":"921_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/S41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2022","unstructured":"Chen PJ, Liu DR (2022) Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet 24:161. https:\/\/doi.org\/10.1038\/S41576-022-00541-1","journal-title":"Nat Rev Genet"},{"key":"921_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41929-025-01406-6","volume":"8","author":"SL Krausz","year":"2025","unstructured":"Krausz SL, Simon DA, Bartos Z et al (2025) ProPE expands the prime editing window and enhances gene editing efficiency where prime editing is inefficient. Nat Catal 2025 8:10. https:\/\/doi.org\/10.1038\/s41929-025-01406-6","journal-title":"Nat Catal 2025"},{"key":"921_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/J.TIBTECH.2023.03.004","volume":"41","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Shang P, Mohanraju P, Geijsen N (2023) Prime editing: advances and therapeutic applications. Trends Biotechnol 41:1000\u20131012. https:\/\/doi.org\/10.1016\/J.TIBTECH.2023.03.004","journal-title":"Trends Biotechnol"},{"key":"921_CR24","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/J.CELL.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert LA, Larson MH, Morsut L et al (2013) CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes. Cell 154:442\u2013451. https:\/\/doi.org\/10.1016\/J.CELL.2013.06.044","journal-title":"Cell"},{"key":"921_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.CBPA.2020.04.020","volume":"57","author":"RAF Gjaltema","year":"2020","unstructured":"Gjaltema RAF, Rots MG (2020) Advances of epigenetic editing. Curr Opin Chem Biol 57:75\u201381. https:\/\/doi.org\/10.1016\/J.CBPA.2020.04.020","journal-title":"Curr Opin Chem Biol"},{"key":"921_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.PREME.2025.100048","volume":"2","author":"J Du","year":"2025","unstructured":"Du J, Wu Q, Liu C et al (2025) CRISPR delivery systems for organ-specific targeting: advances and challenges. Precision Medicine and Engineering 2:100048. https:\/\/doi.org\/10.1016\/J.PREME.2025.100048","journal-title":"Precision Medicine and Engineering"},{"key":"921_CR27","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1038\/s41467-023-42695-4","volume":"14","author":"Q Chen","year":"2023","unstructured":"Chen Q, Chuai G, Zhang H et al (2023) Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints. Nat Commun 14:7521. https:\/\/doi.org\/10.1038\/s41467-023-42695-4","journal-title":"Nat Commun"},{"key":"921_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113765","volume":"43","author":"J Li","year":"2024","unstructured":"Li J, Wu P, Cao Z et al (2024) Machine learning-based prediction models to guide the selection of Cas9 variants for efficient gene editing. Cell Rep 43:113765. https:\/\/doi.org\/10.1016\/j.celrep.2024.113765","journal-title":"Cell Rep"},{"key":"921_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/J.ISCI.2021.103380","volume":"24","author":"JA Morris","year":"2021","unstructured":"Morris JA, Rahman JA, Guo X, Sanjana NE (2021) Automated design of CRISPR prime editors for 56,000 human pathogenic variants. iScience 24:103380. https:\/\/doi.org\/10.1016\/J.ISCI.2021.103380","journal-title":"iScience"},{"key":"921_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22073327","volume":"22","author":"S Nidhi","year":"2021","unstructured":"Nidhi S, Anand U, Oleksak P et al (2021) Novel CRISPR\u2013Cas systems: an updated review of the current achievements, applications, and future research perspectives. Int J Mol Sci 22:3327. https:\/\/doi.org\/10.3390\/IJMS22073327","journal-title":"Int J Mol Sci"},{"key":"921_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/S41588-025-02172-8","author":"Z Matuszek","year":"2025","unstructured":"Matuszek Z, Arbab M, Kesavan M et al (2025) Base editing of trinucleotide repeats that cause Huntington\u2019s disease and Friedreich\u2019s ataxia reduces somatic repeat expansions in patient cells and in mice. Nat Genet. https:\/\/doi.org\/10.1038\/S41588-025-02172-8","journal-title":"Nat Genet"},{"key":"921_CR32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMOA2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD et al (2021) CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia. N Engl J Med 384:252\u2013260. https:\/\/doi.org\/10.1056\/NEJMOA2031054","journal-title":"N Engl J Med"},{"key":"921_CR33","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944204","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV (2024) Editorial: first regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia. Med Sci Monit 30:e944204-1. https:\/\/doi.org\/10.12659\/MSM.944204","journal-title":"Med Sci Monit"},{"key":"921_CR34","doi-asserted-by":"publisher","first-page":"8904","DOI":"10.1007\/S12274-024-6748-5","volume":"17","author":"Z Guo","year":"2024","unstructured":"Guo Z, Zhu AT, Fang RH, Zhang L (2024) Viral and nonviral nanocarriers for in vivo CRISPR-based gene editing. Nano Res 17:8904. https:\/\/doi.org\/10.1007\/S12274-024-6748-5","journal-title":"Nano Res"},{"key":"921_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/S40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR (2017) Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. Biodrugs 31:317. https:\/\/doi.org\/10.1007\/S40259-017-0234-5","journal-title":"Biodrugs"},{"key":"921_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/ACS.ACCOUNTS.9B00106","volume":"52","author":"D Wilbie","year":"2019","unstructured":"Wilbie D, Walther J, Mastrobattista E (2019) Delivery Aspects of CRISPR\/Cas for in Vivo Genome Editing. Acc Chem Res 52:1555. https:\/\/doi.org\/10.1021\/ACS.ACCOUNTS.9B00106","journal-title":"Acc Chem Res"},{"key":"921_CR37","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/S41592-023-01840-Z","volume":"20","author":"RS Zou","year":"2023","unstructured":"Zou RS, Liu Y, Gaido OER et al (2023) Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq. Nat Methods 20:706\u2013713. https:\/\/doi.org\/10.1038\/S41592-023-01840-Z","journal-title":"Nat Methods"},{"key":"921_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/S41596-020-00453-6","volume":"16","author":"D Kim","year":"2021","unstructured":"Kim D, Kang BC, Kim JS (2021) Identifying genome-wide off-target sites of CRISPR RNA-guided nucleases and deaminases with Digenome-seq. Nat Protoc 16:1170\u20131192. https:\/\/doi.org\/10.1038\/S41596-020-00453-6","journal-title":"Nat Protoc"},{"key":"921_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/S41582-020-0373-Z","volume":"16","author":"M Kampmann","year":"2020","unstructured":"Kampmann M (2020) CRISPR-based functional genomics for neurological disease. Nat Rev Neurol 16:465. https:\/\/doi.org\/10.1038\/S41582-020-0373-Z","journal-title":"Nat Rev Neurol"},{"key":"921_CR40","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/J.PRDOA.2020.100056","volume":"3","author":"EM Gatto","year":"2020","unstructured":"Gatto EM, Rojas NG, Persi G et al (2020) Huntington disease: Advances in the understanding of its mechanisms. Clin Park Relat Disord 3:100056. https:\/\/doi.org\/10.1016\/J.PRDOA.2020.100056","journal-title":"Clin Park Relat Disord"},{"key":"921_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/J.ARR.2018.11.006","volume":"49","author":"TR Soares","year":"2019","unstructured":"Soares TR, Reis SD, Pinho BR et al (2019) Targeting the proteostasis network in Huntington\u2019s disease. Ageing Res Rev 49:92\u2013103. https:\/\/doi.org\/10.1016\/J.ARR.2018.11.006","journal-title":"Ageing Res Rev"},{"key":"921_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3233\/JHD-231516","volume":"13","author":"RR Handley","year":"2024","unstructured":"Handley RR, Reid SJ, Burch Z et al (2024) Somatic CAG Repeat Stability in a Transgenic Sheep Model of Huntington\u2019s Disease. J Huntingtons Dis 13:33\u201340. https:\/\/doi.org\/10.3233\/JHD-231516;REQUESTEDJOURNAL:JOURNAL:HUNA;WEBSITE:WEBSITE:SAGE;WGROUP:STRING:PUBLICATION","journal-title":"J Huntingtons Dis"},{"key":"921_CR43","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/NAR\/GKAE1204","volume":"53","author":"E Cattaneo","year":"2025","unstructured":"Cattaneo E, Scalzo D, Zobel M et al (2025) When repetita no-longer iuvant: somatic instability of the CAG triplet in Huntington\u2019s disease. Nucleic Acids Res 53:1204. https:\/\/doi.org\/10.1093\/NAR\/GKAE1204","journal-title":"Nucleic Acids Res"},{"key":"921_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/HMG\/DDY375","volume":"28","author":"R Goold","year":"2018","unstructured":"Goold R, Flower M, Moss DH et al (2018) FAN1 modifies Huntington\u2019s disease progression by stabilizing the expanded HTT CAG repeat. Hum Mol Genet 28:650. https:\/\/doi.org\/10.1093\/HMG\/DDY375","journal-title":"Hum Mol Genet"},{"issue":"2","key":"921_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41588-024-02054-5","volume":"57","author":"R Mouro Pinto","year":"2025","unstructured":"Mouro Pinto R, Murtha R, Azevedo A et al (2025) In vivo CRISPR\u2013Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington\u2019s disease. Nat Genet 2025 57(2):314\u2013322. https:\/\/doi.org\/10.1038\/s41588-024-02054-5","journal-title":"Nat Genet 2025"},{"key":"921_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/J.MITO.2023.03.001","volume":"70","author":"Y Dai","year":"2023","unstructured":"Dai Y, Wang H, Lian A et al (2023) A comprehensive perspective of Huntington\u2019s disease and mitochondrial dysfunction. Mitochondrion 70:8\u201319. https:\/\/doi.org\/10.1016\/J.MITO.2023.03.001","journal-title":"Mitochondrion"},{"key":"921_CR47","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1080\/15548627.2020.1728096","volume":"17","author":"S Franco-Iborra","year":"2020","unstructured":"Franco-Iborra S, Plaza-Zabala A, Montpeyo M et al (2020) Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease. Autophagy 17:672. https:\/\/doi.org\/10.1080\/15548627.2020.1728096","journal-title":"Autophagy"},{"key":"921_CR48","unstructured":"Caron NS, Wright GE, Hayden MR (2020) Huntington Disease. GeneReviews&#174"},{"key":"921_CR49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/14656566.2021.1876666","volume":"22","author":"JS Gibson","year":"2021","unstructured":"Gibson JS, Claassen DO (2021) State-of-the-art pharmacological approaches to reduce chorea in Huntington\u2019s Disease. Expert Opin Pharmacother 22:1015. https:\/\/doi.org\/10.1080\/14656566.2021.1876666","journal-title":"Expert Opin Pharmacother"},{"key":"921_CR50","doi-asserted-by":"publisher","first-page":"117557","DOI":"10.1016\/J.BIOPHA.2024.117557","volume":"180","author":"Jyuan Yao","year":"2024","unstructured":"Yao Jyuan, Liu T, Hu X, ru et al (2024) An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington\u2019s disease treatment. Biomed Pharmacother 180:117557. https:\/\/doi.org\/10.1016\/J.BIOPHA.2024.117557","journal-title":"Biomed Pharmacother"},{"key":"921_CR51","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/ARS.2009.3015","volume":"13","author":"R Santos","year":"2010","unstructured":"Santos R, Lefevre S, Sliwa D et al (2010) Friedreich Ataxia: Molecular Mechanisms, Redox Considerations, and Therapeutic Opportunities. Antioxid Redox Signal 13:651. https:\/\/doi.org\/10.1089\/ARS.2009.3015","journal-title":"Antioxid Redox Signal"},{"key":"921_CR52","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(25)00175-9","volume":"24","author":"K Reetz","year":"2025","unstructured":"Reetz K, Lischewski SA, Dogan I et al (2025) Friedreich\u2019s ataxia\u2014a rare multisystem disease. Lancet Neurol 24:614\u2013624. https:\/\/doi.org\/10.1016\/S1474-4422(25)00175-9","journal-title":"Lancet Neurol"},{"key":"921_CR53","doi-asserted-by":"publisher","first-page":"103385","DOI":"10.1016\/J.DNAREP.2022.103385","volume":"118","author":"C Masnovo","year":"2022","unstructured":"Masnovo C, Lobo AF, Mirkin SM (2022) Replication dependent and independent mechanisms of GAA repeat instability. DNA Repair (Amst) 118:103385. https:\/\/doi.org\/10.1016\/J.DNAREP.2022.103385","journal-title":"DNA Repair (Amst)"},{"key":"921_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen AH (2011) Friedreich\u2019s ataxia: Pathology, pathogenesis, and molecular genetics. J Neurol Sci 303:1\u201312. https:\/\/doi.org\/10.1016\/j.jns.2011.01.010","journal-title":"J Neurol Sci"},{"key":"921_CR55","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41419-023-06320-y","volume":"14","author":"D Davide","year":"2023","unstructured":"Davide D, Federica C, Marco B et al (2023) Human frataxin, the Friedreich ataxia deficient protein, interacts with mitochondrial respiratory chain. Cell Death Disease 2023 14:12. https:\/\/doi.org\/10.1038\/s41419-023-06320-y","journal-title":"Cell Death Disease 2023"},{"key":"921_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/J.BBAMCR.2024.119809","volume":"1871","author":"V Mosbach","year":"2024","unstructured":"Mosbach V, Puccio H (2024) A multiple animal and cellular models approach to study frataxin deficiency in Friedreich ataxia. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1871:119809. https:\/\/doi.org\/10.1016\/J.BBAMCR.2024.119809","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"key":"921_CR57","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/S00415-009-1008-X","volume":"256","author":"JB Schulz","year":"2009","unstructured":"Schulz JB, Di Prospero NA, Fischbeck K (2009) Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol 256:42. https:\/\/doi.org\/10.1007\/S00415-009-1008-X","journal-title":"J Neurol"},{"key":"921_CR58","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/J.MOLMED.2023.12.002","volume":"30","author":"F Pilotto","year":"2024","unstructured":"Pilotto F, Chellapandi DM, Puccio H (2024) Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia. Trends Mol Med 30:117\u2013125. https:\/\/doi.org\/10.1016\/J.MOLMED.2023.12.002","journal-title":"Trends Mol Med"},{"key":"921_CR59","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/J.SCR.2019.101529","volume":"40","author":"J Li","year":"2019","unstructured":"Li J, Rozwadowska N, Clark A et al (2019) Excision of the expanded GAA repeats corrects cardiomyopathy phenotypes of iPSC-derived Friedreich\u2019s ataxia cardiomyocytes. Stem Cell Res 40:101529. https:\/\/doi.org\/10.1016\/J.SCR.2019.101529","journal-title":"Stem Cell Res"},{"key":"921_CR60","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/mt.2015.41","volume":"23","author":"Y Li","year":"2015","unstructured":"Li Y, Polak U, Bhalla AD et al (2015) Excision of expanded GAA repeats alleviates the molecular phenotype of friedreich\u2019s ataxia. Mol Ther 23:1055\u20131065. https:\/\/doi.org\/10.1038\/mt.2015.41","journal-title":"Mol Ther"},{"key":"921_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1089\/HUM.2020.323","volume":"33","author":"SR Oikemus","year":"2022","unstructured":"Oikemus SR, Pfister EL, Sapp E et al (2022) Allele-Specific Knockdown of Mutant Huntingtin Protein via Editing at Coding Region Single Nucleotide Polymorphism Heterozygosities. Hum Gene Ther 33:25. https:\/\/doi.org\/10.1089\/HUM.2020.323","journal-title":"Hum Gene Ther"},{"key":"921_CR62","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.141042","volume":"7","author":"JW Shin","year":"2022","unstructured":"Shin JW, Hong EP, Park SS et al (2022) Allele-specific silencing of the gain-of-function mutation in Huntington\u2019s disease using CRISPR\/Cas9. JCI Insight 7:e141042. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.141042","journal-title":"JCI Insight"},{"key":"921_CR63","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/S40035-023-00376-8","volume":"12","author":"S Maheshwari","year":"2023","unstructured":"Maheshwari S, Vilema-Enr\u00edquez G, Wade-Martins R (2023) Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application. Transl Neurodegener 12:45. https:\/\/doi.org\/10.1186\/S40035-023-00376-8","journal-title":"Transl Neurodegener"},{"key":"921_CR64","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/J.NEURON.2019.01.039","volume":"101","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Ghosh R, Leavitt BR (2019) Huntingtin Lowering Strategies for Disease Modification in Huntington\u2019s Disease. Neuron 101:801\u2013819. https:\/\/doi.org\/10.1016\/J.NEURON.2019.01.039","journal-title":"Neuron"},{"key":"921_CR65","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/382530","author":"W Wan","year":"2015","unstructured":"Wan W, Cao L, Kalionis B et al (2015) Applications of induced pluripotent stem cells in studying the neurodegenerative diseases. Stem Cells Int. https:\/\/doi.org\/10.1155\/2015\/382530","journal-title":"Stem Cells Int"},{"key":"921_CR66","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/J.OMTM.2022.08.005","volume":"26","author":"JW Shin","year":"2022","unstructured":"Shin JW, Hong EP, Park SS et al (2022) PAM-altering SNP-based allele-specific CRISPR-Cas9 therapeutic strategies for Huntington\u2019s disease. Mol Ther Methods Clin Dev 26:547. https:\/\/doi.org\/10.1016\/J.OMTM.2022.08.005","journal-title":"Mol Ther Methods Clin Dev"},{"key":"921_CR67","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/MT.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, McBride JL, Martins I et al (2009) Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington\u2019s Disease Mice. Mol Ther 17:1053. https:\/\/doi.org\/10.1038\/MT.2009.17","journal-title":"Mol Ther"},{"key":"921_CR68","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/J.TCB.2009.01.005","volume":"19","author":"JP Caviston","year":"2009","unstructured":"Caviston JP, Holzbaur ELF (2009) Huntingtin as an Essential Integrator of Intracellular Vesicular Trafficking. Trends Cell Biol 19:147. https:\/\/doi.org\/10.1016\/J.TCB.2009.01.005","journal-title":"Trends Cell Biol"},{"key":"921_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/S13024-024-00794-W","volume":"20","author":"Y Lin","year":"2025","unstructured":"Lin Y, Li C, Chen Y et al (2025) RNA-Targeting CRISPR\/CasRx system relieves disease symptoms in Huntington\u2019s disease models. Mol Neurodegeneration 20:4. https:\/\/doi.org\/10.1186\/S13024-024-00794-W","journal-title":"Mol Neurodegeneration"},{"key":"921_CR70","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/mt.2009.17","volume":"17","author":"RL Boudreau","year":"2009","unstructured":"Boudreau RL, McBride JL, Martins I et al (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice. Mol Ther 17:1053\u20131063. https:\/\/doi.org\/10.1038\/mt.2009.17","journal-title":"Mol Ther"},{"key":"921_CR71","doi-asserted-by":"publisher","first-page":"335124","DOI":"10.3389\/FNINS.2018.00075\/BIBTEX","volume":"12","author":"M Dabrowska","year":"2018","unstructured":"Dabrowska M, Juzwa W, Krzyzosiak WJ, Olejniczak M (2018) Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases. Front Neurosci 12:335124. https:\/\/doi.org\/10.3389\/FNINS.2018.00075\/BIBTEX","journal-title":"Front Neurosci"},{"key":"921_CR72","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/BPA.12427","volume":"26","author":"E Alia Mart","year":"2016","unstructured":"Alia Mart E, Marti E (2016) RNA toxicity induced by expanded CAG repeats in Huntington\u2019s disease. Brain Pathol 26:779. https:\/\/doi.org\/10.1111\/BPA.12427","journal-title":"Brain Pathol"},{"key":"921_CR73","doi-asserted-by":"publisher","first-page":"850","DOI":"10.3390\/GENES16080850","volume":"16","author":"A Akbar","year":"2025","unstructured":"Akbar A, Haider R, Agnello L et al (2025) CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies. Genes 16:850. https:\/\/doi.org\/10.3390\/GENES16080850","journal-title":"Genes"},{"key":"921_CR74","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/S42003-023-04829-8","volume":"6","author":"JH Seo","year":"2023","unstructured":"Seo JH, Shin JH, Lee J et al (2023) DNA double-strand break-free CRISPR interference delays Huntington\u2019s disease progression in mice. Commun Biol 6:466. https:\/\/doi.org\/10.1038\/S42003-023-04829-8","journal-title":"Commun Biol"},{"key":"921_CR75","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/S41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18:358. https:\/\/doi.org\/10.1038\/S41573-019-0012-9","journal-title":"Nat Rev Drug Discov"},{"key":"921_CR76","doi-asserted-by":"publisher","first-page":"115363","DOI":"10.1016\/J.ADDR.2024.115363","volume":"211","author":"D Ye","year":"2024","unstructured":"Ye D, Chukwu C, Yang Y et al (2024) Adeno-associated virus vector delivery to the brain: Technology advancements and clinical applications. Adv Drug Deliv Rev 211:115363. https:\/\/doi.org\/10.1016\/J.ADDR.2024.115363","journal-title":"Adv Drug Deliv Rev"},{"key":"921_CR77","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/J.JCONREL.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha EA, Lee J, Hotta A (2022) Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. J Controlled Release 342:345\u2013361. https:\/\/doi.org\/10.1016\/J.JCONREL.2022.01.013","journal-title":"J Controlled Release"},{"key":"921_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/NCOMMS14500","volume":"8","author":"E Kim","year":"2017","unstructured":"Kim E, Koo T, Park SW et al (2017) In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nat Commun 8:14500. https:\/\/doi.org\/10.1038\/NCOMMS14500","journal-title":"Nat Commun"},{"key":"921_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPHARM.2025.125470","volume":"674","author":"S Honrath","year":"2025","unstructured":"Honrath S, Burger M, Leroux JC (2025) Hurdles to healing: overcoming cellular barriers for viral and nonviral gene therapy. Int J Pharm 674:125470. https:\/\/doi.org\/10.1016\/J.IJPHARM.2025.125470","journal-title":"Int J Pharm"},{"key":"921_CR80","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/S41434-023-00387-0","volume":"30","author":"P Yam\u00e9ogo","year":"2023","unstructured":"Yam\u00e9ogo P, G\u00e9rard C, Majeau N, Tremblay JP (2023) Removal of the GAA repeat in the heart of a Friedreich\u2019s ataxia mouse model using CjCas9. Gene Ther 30:612\u2013619. https:\/\/doi.org\/10.1038\/S41434-023-00387-0","journal-title":"Gene Ther"},{"key":"921_CR81","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1242\/dmm.018952","volume":"8","author":"SA Virmouni","year":"2015","unstructured":"Virmouni SA, Ezzatizadeh V, Sandi C et al (2015) A novel GAA-repeat-expansion-based mouse model of Friedreich\u2019s ataxia. DMM Disease Models Mech 8:225\u2013235. https:\/\/doi.org\/10.1242\/dmm.018952","journal-title":"DMM Disease Models Mech"},{"key":"921_CR82","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/gt.2016.89","volume":"24","author":"DL Ouellet","year":"2017","unstructured":"Ouellet DL, Cherif K, Rousseau J, Tremblay JP (2017) Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia. Gene Ther 24:265\u2013274. https:\/\/doi.org\/10.1038\/gt.2016.89","journal-title":"Gene Ther"},{"issue":"1 10","key":"921_CR83","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/S13287-019-1305-Y","volume":"10","author":"AOT Wong","year":"2019","unstructured":"Wong AOT, Wong G, Shen M et al (2019) Correlation between frataxin expression and contractility revealed by in vitro Friedreich\u2019s ataxia cardiac tissue models engineered from human pluripotent stem cells. Stem Cell Res Therapy 2019 10(1 10):203\u2013. https:\/\/doi.org\/10.1186\/S13287-019-1305-Y","journal-title":"Stem Cell Res Therapy 2019"},{"key":"921_CR84","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1089\/SCD.2016.0147","volume":"25","author":"U Polak","year":"2016","unstructured":"Polak U, Li Y, Butler JS, Napierala M (2016) Alleviating GAA Repeat Induced Transcriptional Silencing of the Friedreich\u2019s Ataxia Gene During Somatic Cell Reprogramming. Stem Cells Dev 25:1788. https:\/\/doi.org\/10.1089\/SCD.2016.0147","journal-title":"Stem Cells Dev"},{"key":"921_CR85","doi-asserted-by":"publisher","first-page":"7834175","DOI":"10.1155\/2018\/7834175","volume":"2018","author":"N Xie","year":"2018","unstructured":"Xie N, Zhou Y, Sun Q, Tang B (2018) Novel Epigenetic Techniques Provided by the CRISPR\/Cas9 System. Stem Cells Int 2018:7834175. https:\/\/doi.org\/10.1155\/2018\/7834175","journal-title":"Stem Cells Int"},{"key":"921_CR86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/J.OMTN.2018.04.009","volume":"12","author":"K Cherif","year":"2018","unstructured":"Cherif K, G\u00e9rard C, Rousseau J et al (2018) Increased Frataxin Expression Induced in Friedreich Ataxia Cells by Platinum TALE-VP64s or Platinum TALE-SunTag. Mol Ther Nucleic Acids 12:19. https:\/\/doi.org\/10.1016\/J.OMTN.2018.04.009","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5 24","key":"921_CR87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/gt.2016.89","volume":"24","author":"DL Ouellet","year":"2016","unstructured":"Ouellet DL, Cherif K, Rousseau J, Tremblay JP (2016) Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia. Gene Therapy 2017 24(5 24):265\u2013274. https:\/\/doi.org\/10.1038\/gt.2016.89","journal-title":"Gene Therapy 2017"},{"key":"921_CR88","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/J.OMTM.2020.04.018","volume":"17","author":"CJ Rocca","year":"2020","unstructured":"Rocca CJ, Rainaldi JN, Sharma J et al (2020) CRISPR-Cas9 Gene Editing of Hematopoietic Stem Cells from Patients with Friedreich\u2019s Ataxia. Mol Ther Methods Clin Dev 17:1026. https:\/\/doi.org\/10.1016\/J.OMTM.2020.04.018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"921_CR89","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAJ2347","volume":"9","author":"CJ Rocca","year":"2017","unstructured":"Rocca CJ, Goodman SM, Dulin JN et al (2017) Transplantation of wild-type mouse hematopoietic stem and progenitor cells ameliorates deficits in a mouse model of Friedreich\u2019s ataxia. Sci Transl Med 9:eaaj2347. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAJ2347","journal-title":"Sci Transl Med"},{"key":"921_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/J.OMTM.2024.101357","volume":"32","author":"L Zhou","year":"2024","unstructured":"Zhou L, Wang Y, Xu Y et al (2024) Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders. Mol Ther 32:101357. https:\/\/doi.org\/10.1016\/J.OMTM.2024.101357","journal-title":"Mol Ther"},{"key":"921_CR91","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/S12264-022-00880-3","volume":"38","author":"Y Qin","year":"2022","unstructured":"Qin Y, Li S, Li XJ, Yang S (2022) CRISPR-Based Genome-Editing Tools for Huntington\u2019s Disease Research and Therapy. Neurosci Bull 38:1397. https:\/\/doi.org\/10.1007\/S12264-022-00880-3","journal-title":"Neurosci Bull"},{"key":"921_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2026.04.038","author":"K Tan","year":"2026","unstructured":"Tan K, Del Bosque Siller D, Xiong AY et al (2026) Treatment of Huntington\u2019s disease with a pan-HTT-targeting CRISPR nuclease. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.038","journal-title":"Mol Ther"},{"key":"921_CR93","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/S13311-019-00810-8","volume":"16","author":"S Naphade","year":"2019","unstructured":"Naphade S, Tshilenge KT, Ellerby LM (2019) Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells. Neurotherapeutics 16:979\u2013998. https:\/\/doi.org\/10.1007\/S13311-019-00810-8","journal-title":"Neurotherapeutics"},{"key":"921_CR94","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/J.YMTHE.2023.03.024","volume":"31","author":"L Bendixen","year":"2023","unstructured":"Bendixen L, Jensen TI, Bak RO (2023) CRISPR-Cas-mediated transcriptional modulation: the therapeutic promises of CRISPRa and CRISPRi. Mol Ther 31:1920. https:\/\/doi.org\/10.1016\/J.YMTHE.2023.03.024","journal-title":"Mol Ther"},{"key":"921_CR95","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/NATURE17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS et al (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533:420\u2013424. https:\/\/doi.org\/10.1038\/NATURE17946","journal-title":"Nature"},{"key":"921_CR96","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1002\/JGM.70040","volume":"27","author":"M Aliciaslan","year":"2025","unstructured":"Aliciaslan M, Erbasan E, Erendor F, Sanlioglu S (2025) Prime Editing: The Next Frontier in Precision Gene Therapy. J Gene Med 27:e70040. https:\/\/doi.org\/10.1002\/JGM.70040;SUBPAGE:STRING:ABSTRACT;WEBSITE:WEBSITE:PERICLES;ISSUE:ISSUE:DOI","journal-title":"J Gene Med"},{"key":"921_CR97","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/MT.2015.41","volume":"23","author":"Y Li","year":"2015","unstructured":"Li Y, Polak U, Bhalla AD et al (2015) Excision of Expanded GAA Repeats Alleviates the Molecular Phenotype of Friedreich\u2019s Ataxia. Mol Ther 23:1055. https:\/\/doi.org\/10.1038\/MT.2015.41","journal-title":"Mol Ther"},{"key":"921_CR98","doi-asserted-by":"publisher","first-page":"852080","DOI":"10.1155\/2013\/852080","volume":"2013","author":"C Sandi","year":"2013","unstructured":"Sandi C, Al-Mahdawi S, Pook MA (2013) Epigenetics in Friedreich\u2019s Ataxia: Challenges and Opportunities for Therapy. Genet Res Int 2013:852080. https:\/\/doi.org\/10.1155\/2013\/852080","journal-title":"Genet Res Int"},{"key":"921_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS241914865","volume":"24","author":"R Cai","year":"2023","unstructured":"Cai R, Lv R, Shi X et al (2023) CRISPR\/dCas9 tools: epigenetic mechanism and application in gene transcriptional regulation. Int J Mol Sci 24:14865. https:\/\/doi.org\/10.3390\/IJMS241914865","journal-title":"Int J Mol Sci"},{"key":"921_CR100","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.3390\/IJMS26136371\/S1","volume":"26","author":"MA Kovalev","year":"2025","unstructured":"Kovalev MA, Mamaeva NY, Kristovskiy NV et al (2025) Epigenome Engineering Using dCas Systems for Biomedical Applications and Biotechnology: Current Achievements, Opportunities and Challenges. Int J Mol Sci 26:6371. https:\/\/doi.org\/10.3390\/IJMS26136371\/S1","journal-title":"Int J Mol Sci"},{"issue":"6 57","key":"921_CR101","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41588-025-02172-8","volume":"57","author":"Z Matuszek","year":"2025","unstructured":"Matuszek Z, Arbab M, Kesavan M et al (2025) Base editing of trinucleotide repeats that cause Huntington\u2019s disease and Friedreich\u2019s ataxia reduces somatic repeat expansions in patient cells and in mice. Nat Genet 2025 57(6 57):1437\u20131451. https:\/\/doi.org\/10.1038\/s41588-025-02172-8","journal-title":"Nat Genet 2025"},{"key":"921_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/MCO2.70389","volume":"6","author":"JM Li","year":"2025","unstructured":"Li JM, Huang J, Liao Y et al (2025) Gene and RNA editing: revolutionary approaches to treating diseases. MedComm 6:e70389. https:\/\/doi.org\/10.1002\/MCO2.70389","journal-title":"MedComm"},{"key":"921_CR103","doi-asserted-by":"publisher","first-page":"502159","DOI":"10.3389\/FNAGI.2019.00373\/FULL","volume":"11","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM (2020) Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. Front Aging Neurosci 11:502159. https:\/\/doi.org\/10.3389\/FNAGI.2019.00373\/FULL","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"921_CR104","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP et al (2016) Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 2015 34(2):204\u2013209. https:\/\/doi.org\/10.1038\/nbt.3440","journal-title":"Nat Biotechnol 2015"},{"issue":"1","key":"921_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42386-0","volume":"14","author":"LM Riedmayr","year":"2023","unstructured":"Riedmayr LM, Hinrichsmeyer KS, Thalhammer SB et al (2023) MRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy. Nat Commun 14(1):6578. https:\/\/doi.org\/10.1038\/s41467-023-42386-0","journal-title":"Nat Commun"},{"key":"921_CR106","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.3390\/IJMS241310524\/S1","volume":"24","author":"MV Ferreira","year":"2023","unstructured":"Ferreira MV, Fernandes S, Almeida AI et al (2023) Extending AAV Packaging Cargo through Dual Co-Transduction: Efficient Protein Trans-Splicing at Low Vector Doses. Int J Mol Sci 24:10524. https:\/\/doi.org\/10.3390\/IJMS241310524\/S1","journal-title":"Int J Mol Sci"},{"key":"921_CR107","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH (2019) Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality. Neuron 101:839\u2013862. https:\/\/doi.org\/10.1016\/j.neuron.2019.02.017","journal-title":"Neuron"},{"key":"921_CR108","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/ACS.MOLPHARMACEUT.1C00916","volume":"19","author":"P Kazemian","year":"2022","unstructured":"Kazemian P, Yu SY, Thomson SB et al (2022) Lipid-Nanoparticle-Based Delivery of CRISPR\/Cas9 Genome-Editing Components. Mol Pharm 19:1669. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.1C00916","journal-title":"Mol Pharm"},{"key":"921_CR109","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1016\/J.APSB.2026.02.014","volume":"16","author":"J Yang","year":"2026","unstructured":"Yang J, Chen Y, Chen X, Ping Y (2026) Non-viral delivery of genome-editing tools for treatment of genetic disorders. Acta Pharm Sin B 16:2903\u20132928. https:\/\/doi.org\/10.1016\/J.APSB.2026.02.014","journal-title":"Acta Pharm Sin B"},{"key":"921_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS25137333","volume":"25","author":"M Taghdiri","year":"2024","unstructured":"Taghdiri M, Mussolino C (2024) Viral and non-viral systems to deliver gene therapeutics to clinical targets. Int J Mol Sci 25:7333. https:\/\/doi.org\/10.3390\/IJMS25137333","journal-title":"Int J Mol Sci"},{"key":"921_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/J.XCRM.2025.102459","volume":"7","author":"R Ji","year":"2026","unstructured":"Ji R, Chen Q, Zhang Y (2026) Emerging trends in gene and cell therapy: CRISPR in DNA editing and beyond. Cell Rep Med 7:102459. https:\/\/doi.org\/10.1016\/J.XCRM.2025.102459","journal-title":"Cell Rep Med"},{"key":"921_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/S12035-025-05417-Z","volume":"63","author":"U Kochman","year":"2025","unstructured":"Kochman U, Sitka H, Ku\u017aniar J et al (2025) Targeted nanoparticles for drug delivery across the blood\u2013brain barrier in early and late stages of Alzheimer\u2019s disease: a review. Mol Neurobiol 63:75. https:\/\/doi.org\/10.1007\/S12035-025-05417-Z","journal-title":"Mol Neurobiol"},{"key":"921_CR113","doi-asserted-by":"publisher","first-page":"25910","DOI":"10.1039\/D5RA03578C","volume":"15","author":"D Senanayake","year":"2025","unstructured":"Senanayake D, Yapa P, Dabare S, Munaweera I (2025) Precision targeting of the CNS: recent progress in brain-directed nanodrug delivery. RSC Adv 15:25910. https:\/\/doi.org\/10.1039\/D5RA03578C","journal-title":"RSC Adv"},{"issue":"1","key":"921_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19230-w","volume":"11","author":"J Weinmann","year":"2020","unstructured":"Weinmann J, Weis S, Sippel J et al (2020) Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. Nat Commun 11(1):5432. https:\/\/doi.org\/10.1038\/s41467-020-19230-w","journal-title":"Nat Commun"},{"key":"921_CR115","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/J.YMTHE.2019.07.017","volume":"27","author":"WA Liguore","year":"2019","unstructured":"Liguore WA, Domire JS, Button D et al (2019) AAV-PHP.B administration results in a differential pattern of CNS biodistribution in non-human primates compared with mice. Mol Ther 27:2018. https:\/\/doi.org\/10.1016\/J.YMTHE.2019.07.017","journal-title":"Mol Ther"},{"key":"921_CR116","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1101\/GAD.301325.117","volume":"31","author":"PJ McKinnon","year":"2017","unstructured":"McKinnon PJ (2017) Genome integrity and disease prevention in the nervous system. Genes Dev 31:1180. https:\/\/doi.org\/10.1101\/GAD.301325.117","journal-title":"Genes Dev"},{"key":"921_CR117","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/S13059-025-03851-9","volume":"26","author":"M Wang","year":"2025","unstructured":"Wang M, Zhang Y, Bi C, Li M (2025) CRISPR-Cas9-induced double-strand breaks disrupt maintenance of epigenetic information. Genome Biol 26:411. https:\/\/doi.org\/10.1186\/S13059-025-03851-9","journal-title":"Genome Biol"},{"key":"921_CR118","doi-asserted-by":"publisher","unstructured":"Slaymaker IM, Gao L, Zetsche B et al (2016) Rationally engineered Cas9 nucleases with improved specificity. Science (1979) 351:84\u201388. https:\/\/doi.org\/10.1126\/SCIENCE.AAD5227;PAGE:STRING:ARTICLE\/CHAPTER","DOI":"10.1126\/SCIENCE.AAD5227;PAGE:STRING:ARTICLE\/CHAPTER"},{"key":"921_CR119","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas CA, Dever DP, Rettig GR et al (2018) A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med 2018 24:8. https:\/\/doi.org\/10.1038\/s41591-018-0137-0","journal-title":"Nat Med 2018"},{"key":"921_CR120","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees HA, Liu DR (2018) Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 19:770\u2013788. https:\/\/doi.org\/10.1038\/s41576-018-0059-1","journal-title":"Nat Rev Genet"},{"key":"921_CR121","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/GR.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim S, Kim D, Cho SW et al (2014) Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 24:1012\u20131019. https:\/\/doi.org\/10.1101\/GR.171322.113","journal-title":"Genome Res"},{"key":"921_CR122","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/ANNUREV-IMMUNOL-051116-052358\/CITE\/REFWORKS","volume":"35","author":"M Colonna","year":"2017","unstructured":"Colonna M, Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol 35:441\u2013468. https:\/\/doi.org\/10.1146\/ANNUREV-IMMUNOL-051116-052358\/CITE\/REFWORKS","journal-title":"Annu Rev Immunol"},{"key":"921_CR123","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP et al (2019) Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25:249\u2013254. https:\/\/doi.org\/10.1038\/s41591-018-0326-x","journal-title":"Nat Med"},{"key":"921_CR124","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/S41573-019-0012-9;SUBJMETA","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18:358\u2013378. https:\/\/doi.org\/10.1038\/S41573-019-0012-9;SUBJMETA","journal-title":"Nat Rev Drug Discov"},{"key":"921_CR125","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1089\/HUM.2013.005","volume":"24","author":"L Samaranch","year":"2013","unstructured":"Samaranch L, Salegio EA, San Sebastian W et al (2013) Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther 24:526\u2013532. https:\/\/doi.org\/10.1089\/HUM.2013.005","journal-title":"Hum Gene Ther"},{"key":"921_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS14191497","volume":"14","author":"T Vishnumukkala","year":"2025","unstructured":"Vishnumukkala T, Che Mohd Nassir CMN, Hein ZM et al (2025) Glial cells as emerging therapeutic targets in neurodegenerative diseases: mechanistic insights and translational perspectives. Cells 14:1497. https:\/\/doi.org\/10.3390\/CELLS14191497","journal-title":"Cells"},{"key":"921_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2020.104963","volume":"143","author":"DK Wilton","year":"2020","unstructured":"Wilton DK, Stevens B (2020) The contribution of glial cells to Huntington\u2019s disease pathogenesis. Neurobiol Dis 143:104963. https:\/\/doi.org\/10.1016\/J.NBD.2020.104963","journal-title":"Neurobiol Dis"},{"key":"921_CR128","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/J.CELL.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu PD, Lander ES, Zhang F (2014) Development and Applications of CRISPR-Cas9 for Genome Engineering. Cell 157:1262\u20131278. https:\/\/doi.org\/10.1016\/J.CELL.2014.05.010","journal-title":"Cell"},{"key":"921_CR129","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/S41588-025-02172-8","volume":"57","author":"Z Matuszek","year":"2025","unstructured":"Matuszek Z, Arbab M, Kesavan M et al (2025) Base editing of trinucleotide repeats that cause Huntington\u2019s disease and Friedreich\u2019s ataxia reduces somatic repeat expansions in patient cells and in mice. Nat Genet 57:1437. https:\/\/doi.org\/10.1038\/S41588-025-02172-8","journal-title":"Nat Genet"},{"key":"921_CR130","doi-asserted-by":"publisher","first-page":"7544","DOI":"10.1038\/519410a","volume":"519","author":"E Lanphier","year":"2015","unstructured":"Lanphier E, Urnov F, Haecker SE et al (2015) Don\u2019t edit the human germ line. Nat 2015 519:7544. https:\/\/doi.org\/10.1038\/519410a","journal-title":"Nat 2015"},{"key":"921_CR131","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/JAPP.12249","volume":"34","author":"C Gyngell","year":"2017","unstructured":"Gyngell C, Douglas T, Savulescu J (2017) The Ethics of Germline Gene Editing. J Appl Philos 34:498\u2013513. https:\/\/doi.org\/10.1111\/JAPP.12249;WGROUP:STRING:PUBLICATION","journal-title":"J Appl Philos"},{"key":"921_CR132","doi-asserted-by":"crossref","unstructured":"Zuo E, Sun Y, Wei W et al (2019) Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science (1979) 364:289\u2013292. https:\/\/doi.org\/10.1126\/SCIENCE.AAV9973;SUBPAGE:STRING:ABSTRACT;WEBSITE:WEBSITE:AAAS-SITE;JOURNAL:JOURNAL:SCIENCE;WGROUP:STRING:PUBLICATION","DOI":"10.1126\/science.aav9973"},{"key":"921_CR133","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/CRISPR.2020.0082","volume":"3","author":"F Baylis","year":"2020","unstructured":"Baylis F, Darnovsky M, Hasson K, Krahn TM (2020) Human germ line and heritable genome editing: the global policy landscape. CRISPR J 3:365\u2013377. https:\/\/doi.org\/10.1089\/CRISPR.2020.0082","journal-title":"CRISPR J"},{"key":"921_CR134","unstructured":"WHO (2021) Human genome editing: recommendations. 49"},{"key":"921_CR135","unstructured":"Human Gene Therapy for Neurodegenerative Diseases | FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-neurodegenerative-diseases. Accessed 30 Nov 2025"},{"key":"921_CR136","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/J.CELL.2018.03.005","volume":"173","author":"S Yan","year":"2018","unstructured":"Yan S, Tu Z, Liu Z et al (2018) A huntingtin knock-in pig model recapitulates features of selective neurodegeneration in Huntington\u2019s disease. Cell 173:989. https:\/\/doi.org\/10.1016\/J.CELL.2018.03.005","journal-title":"Cell"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00921-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-026-00921-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-026-00921-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:02:06Z","timestamp":1783969326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-026-00921-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s10048-026-00921-3","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}